NASDAQ · ANL
Adlai Nortye Ltd.
$10.28+$0.08 (+0.78%)
Adlai Nortye Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.41% below the high.
Loading market information…
NASDAQ · EKSO · USD
Stock price, earnings
Quote as of Jul 2, 2026, 07:24 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Ekso Bionics Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 40.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ekso Bionics Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ekso Bionics Holdings, Inc. designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable robotic exoskeleton; Ekso Indego Therapy, a powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; and Ekso EVO, a wearable upper body exoskeleton. It also develops Ekso Nomad, a power Knee Ankle Foot Orthosis or KAFO; and MediTouch BalanceTutor rehabilitation system, a multidirectional perturbation treadmill outfitted. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $5.09M+0.79% vs estimate |
| Q3 2024 | Oct 28, 2024 | -$1.50-25.0% vs estimate | $4.13M-25.6% vs estimate |
|---|
| Q2 2024 | Jul 29, 2024 | -$1.95-1,400.0% vs estimate | $4.95M-3.88% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.28+$0.08 (+0.78%)
Adlai Nortye Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.41% below the high.
$1.98+$0.01 (+0.51%)
Aytu BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.5% below the high.
$7.02+$0.28 (+4.08%)
enVVeno Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 73.37% below the high.
$0.12$0.00 (0.0%)
OSR Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.17% below the high.
$2.11+$0.13 (+6.57%)
Ernexa Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.6% below the high.
$0.40-$0.05 (-10.49%)
Co-Diagnostics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.41% below the high.
$5.52-$0.03 (-0.54%)
Aethlon Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.6% below the high.
$0.19-$0.01 (-6.25%)
GeoVax Labs, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.72% below the high.
